Patents by Inventor Jeffrey George Andrew Walton

Jeffrey George Andrew Walton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190106460
    Abstract: The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (?TrCP), and modulate the activity of ?TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.
    Type: Application
    Filed: September 12, 2018
    Publication date: April 11, 2019
    Inventors: Mark Bradley, Jeffrey George Andrew Walton, Sunay Vijaykumar Chankeshwara, Mazen Sleiman, George S. Baillie, Lucien Gibson
  • Publication number: 20140315784
    Abstract: The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.
    Type: Application
    Filed: June 27, 2012
    Publication date: October 23, 2014
    Inventors: Mark Bradley, Jeffrey George Andrew Walton, Sunay Vijaykumar Chankeshwara, Mazen Sleiman, George S. Baillie, Lucien Gibson